Mode
Text Size
Log in / Sign up
Phase 4 N=93 Randomized Single-blind Supportive Care

The Ultrasound Guided Pericapsular Nerve Group and Anterior Quadratus Lumborum Blocks in Hip Replacement Surgeries

Post Operative Analgesia

Enrolled (actual)
93
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: The Total Amount of Morphine Consumption — 6.0; 8.0; 12.0 mg of IV morphine — p=0.035

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Anterior quadratus lumborum block technique (AQLB) (Procedure); Pericapsular Nerve Group (PENG) block (Procedure); Control Group (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Cairo University
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
The Total Amount of Morphine Consumption
6.0; 8.0; 12.0 0.035 sig
SECONDARY
Numeric Pain Rating Scale at Rest Over First 24 Hours
0.0; 1.0; 2.0; 1.0; 1.0; 2.0
SECONDARY
Numeric Pain Rating Scale During Passive 90° Hip Flexion Over First 24 Hours
1.0; 1.0; 3.0; 2.0; 1.0; 5.0
SECONDARY
Time to First Rescue Morphine Analgesia
12.0; 8.0; 2.0
SECONDARY
Manual Muscle Test (MMT) Score for Quadriceps/Iliopsoas Over First 24 Hours
1.0; 2.0; 0.0; 1.0; 3.0; 1.0
SECONDARY
Active Hip Flexion Range of Motion (0°-90°) Over First 24 Hours
0.0; 20.0; 0.0; 0.0; 30.0; 20.0
SECONDARY
Total Intraoperative Fentanyl Dose
142.58; 152.90; 236.61
SECONDARY
Time to First Walk
24.0; 8.0; 18.0
SECONDARY
Length of Hospital Stay
3.16; 2.13; 2.94

Summary

The investigators hypothesis that PENG block will produce effective opioid sparing analgesia with enhanced motor recovery more than AQLB in elderly patients undergoing total hip replacement surgeries

Eligibility Criteria

Inclusion Criteria

  • Both genders
  • Type of surgery; unilateral elective total hip replacement.
  • Physical status ASA I- III
  • Age ≥ 65 Years.
  • Body mass index (BMI): > 20 kg/m2 and 3 folds) or severe kidney disease (creatinine >2).
  • long operative time more than 3 hours.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06679764). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search